2 results match your criteria: "University of Verona. giovanni.adami@univr.it.[Affiliation]"
Novel genetic mutation associated with hyperphosphatemic familial tumoral calcinosis/hyperostosis-hyperphosphatemia syndrome treated with denosumab: a case report.
Reumatismo
June 2024
Rheumatology Unit, Integrated University Hospital of Verona, University of Verona.
Article Synopsis
- A new case report describes a specific mutation (c.782 G>A; p.R261Q) in the N-acetylgalactosaminyltransferase 3 gene linked to a rare syndrome causing hyperphosphatemia and calcinosis.
- * The patient experienced significant pain in the elbow, pelvis, and legs, along with hard masses in specific areas, and showed elevated levels of inorganic phosphorus and C-reactive protein.
- * Treatment included conventional medications and denosumab, which lowered phosphorus levels but did not fully normalize them.*
Secukinumab retention rate is greater in patients with psoriatic arthritis presenting with axial involvement.
Reumatismo
May 2023
Rheumatology Unit, University of Verona.
Psoriatic arthritis (PsA) is an inflammatory disease characterized by peripheral and axial involvement. Biological disease-modifying antirheumatic drugs (bDMARDs) are the mainstream treatment for PsA and bDMARDs retention rate is a proxy for the drug's overall effectiveness. However, it is unclear whether IL-17 inhibitors can have a higher retention rate than tumor necrosis factor (TNF) inhibitors, in particular in axial or peripheral PsA.
View Article and Find Full Text PDF